Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment

Phase 1/2 Unknown 37 enrolled National Taiwan University Hospital National Health Research Institutes, Taiwan · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The specific aims of this study are as follows: 1. Primary endpoint: to evaluate the clinical responses of vaccinated patients. 2. Secondary endpoint: to evaluate the safety of this treatment and the immune responses against CEA before and after the treatment

Timeline

Start: 2005-07
Primary completion: —
Completion: 2005-07

Publications

Liu KJ, Chao TY, Chang JY, Cheng AL, Ch'ang HJ, Kao WY, Wu YC, Yu WL, Chung TR, Whang-Peng J. A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment. J Biomed Sci. 2016 Aug 24;23(1):64. doi: 10.1186/s12929-016-0279-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CEA pulsed dendritic cells	Cell therapy	1e+06 cells	Subcutaneous

Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment

Summary

Timeline

Publications

Drugs

Indications